发明公开
EP1907424A2 HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
有权
人单克隆抗体的程序性死亡配体1(PD-L1)
- 专利标题: HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
- 专利标题(中): 人单克隆抗体的程序性死亡配体1(PD-L1)
-
申请号: EP06786260.7申请日: 2006-06-30
-
公开(公告)号: EP1907424A2公开(公告)日: 2008-04-09
- 发明人: KORMAN, Alan, J. , SELBY, Mark, J. , WANG, Changyu , SRINIVASAN, Mohan , PASSMORE, David, B. , HUANG, Haichun , CHEN, Haibin
- 申请人: MEDAREX, INC.
- 申请人地址: 707 State Road Princeton, NJ 08540 US
- 专利权人: MEDAREX, INC.
- 当前专利权人: MEDAREX, INC.
- 当前专利权人地址: 707 State Road Princeton, NJ 08540 US
- 代理机构: Tuxworth, Pamela M.
- 优先权: US696426P 20050701
- 国际公布: WO2007005874 20070111
- 主分类号: C07K16/28
- IPC分类号: C07K16/28
摘要:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
公开/授权文献
信息查询